|
Genedrive PLC on Wednesday announced follow-on funding of £200,000 for further improvements to user experiences in rapid genetic testing environments. The Manchester-based point-of-care pharmacogenetic testing company said the follow-on award from Innovate UK and the UK Government‘s Innovation Accelerator programme will provide it with £200,000 over the next six months. The new funding builds on Genedrive’s previous ‘success’ in the Devote programme, through which it received around £1.2 million in combined direct grant income, partner contributions and related support. The Devote programme provided Genedrive with acute care patient access and supporting infrastructure to assess real-world clinical performances of time-critical clinical tests in NHS settings. Genedrive’s Chief Executive Officer Gino Miele said: ‘The Devote programme has been an incredible success and follow-on funding provides a further opportunity for us to partner once again with the University of Manchester in continuing development of time-critical genetic test solutions.’ The Devote programme’s lead partner, the University of Manchester, supported the validation, UKCA certification, and implementation of the Genedrive CYP2C19-ID kit. The UK’s National Institute for Health & Care Excellence recommended the Genedrive CYP2C19-ID kit as ‘the rapid genetics platform of choice for use in the NHS for clopidogrel genotyping after ischaemic or transient ischaemic attack.’ Genedrive shares were flat at 1.52 pence each in London on Wednesday afternoon. Copyright 2025 Alliance News Ltd. All Rights reserved.
|
